FDA Approves UCB's Briviact To Treat Partial Onset Seizures During Epilepsy

The U.S. FDA has approved Briviact (brivaracetam), marketed by UCB, Inc., as an add-on treatment to other medications to treat partial onset seizures in patients age 16 years and older with epilepsy. FDA said, Briviact, taken along with other medications, was shown to be effective in reducing the frequency of seizures. Briviact's effectiveness was studied in three clinical trials involving 1,550 participants.

from RTT - Biotech http://ift.tt/1Q7oG4I
via IFTTT